AIM ImmunoTech announces publication on effect of Ampligen

AIM ImmunoTech (AIM) announced that the Journal for ImmunoTherapy of Cancer has published a new peer-reviewed article providing evidence of a positive combination effect of AIM’s drug Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The paper concluded that the ability of systemic chemokine modulation to eliminate the PD-1-resistance of cold tumors indicates that intratumoral cytotoxic t-lymphocyte accumulation, rather than tumor immunogenicity, is the key factor limiting the therapeutic effectiveness of immune checkpoint inhibitors. These data suggest a broad therapeutic potential of tumor microenvironment reprogramming strategies. The article, titled “Synergy between TLR3-ligand and IFN-alpha in the transient sensitization of ‘Cold’ tumors to PD-1 blockade and the induction of systemic immunity,” was published in JITC on September 18.